Impact of Parkinson’s Disease on Lifespan and Survival
Understanding Synucleinopathies
When diagnosed with a serious illness, many individuals seek to understand how their condition will influence their lives and longevity. A recent investigation conducted by the Mayo Clinic examined survival rates and causes of death among individuals with Parkinson’s disease and related synucleinopathies compared to the general population. Synucleinopathies are neurodegenerative disorders characterized by abnormal alpha-synuclein protein deposits in neurons and nerve fibers. The three primary types of synucleinopathy include:
– Parkinson’s disease
– Dementia with Lewy bodies (characterized by clumps of alpha-synuclein proteins in the brain)
– Multiple system atrophy
Despite their unique symptoms and prognoses, all three are associated with reduced lifespans.
Mayo Clinic Study Overview
In a 2017 article published in JAMA Neurology, researchers at the Mayo Clinic in Rochester, Minnesota, conducted a comprehensive population-based study to compare survival and causes of death among patients diagnosed with the three types of synucleinopathy. The researchers analyzed medical records from 1991 to 2010, utilizing the Rochester Epidemiology Project, which encompasses data from Olmsted, Minnesota’s general population.
They identified 461 individuals diagnosed with synucleinopathies manifesting Parkinson’s-like symptoms, including rest tremor, movement slowness, rigidity, and impaired postural reflexes. This group was categorized as follows:
– Parkinson’s disease (N=309)
– Parkinson’s disease with dementia (N=55)
– Dementia with Lewy bodies and parkinsonism (N=81)
– Multiple system atrophy with parkinsonism (N=16)
Each individual was matched by sex and age with another resident from Olmsted who did not have parkinsonism, with approximately 60% of participants being male.
Findings on Lifespan and Mortality
Over a span of 19 years, it was found that 68.6% of patients with synucleinopathies passed away, compared to 48.7% of the matched residents. Through the analysis of death certificates and Kaplan-Meier survival curves, the study revealed that individuals with multiple system atrophy and Parkinson’s-like symptoms faced the highest mortality risk, with an average lifespan reduction of six years.
Other findings indicated:
– Individuals with dementia with Lewy bodies died approximately four years earlier.
– Those with Parkinson’s disease accompanied by dementia had a lifespan reduction of about 3.5 years.
– Patients with Parkinson’s disease alone typically lived 1.75 years less than their matched counterparts.
These differences in lifespan among the various disorders may be attributed to varying disease severities and the rates and locations of alpha-synuclein protein accumulation.
Causes of Death Comparison
Among patients diagnosed with synucleinopathy, neurodegeneration was the leading cause of death (31.5%), followed by cardiovascular disease (15.7%). In contrast, the most common cause of death in the comparison group was cardiovascular events (25.5%), followed by cancer (18.1%). Notably, women in both groups lived an average of two years longer than men.
Significance of the Study
This research represents one of the initial studies to assess survival rates and causes of death among individuals with synucleinopathies in relation to the general population. The authors suggest that these findings can assist healthcare providers in offering better guidance to patients and caregivers regarding their expectations following a diagnosis.
However, the study does not address how treatment and lifestyle choices may influence these lifespan outcomes. Individuals living with Parkinson’s and related diseases often experience many years with their condition. Consequently, healthcare professionals are encouraged to adopt a personalized approach in prognosis, treatment, and financial counseling.
Conclusion
The insights gained from this study are valuable for understanding the implications of synucleinopathies on longevity and can aid in enhancing patient care and support.